Starpharma HoldingsASX:SPL +0.72%52 Days Payable is 1,034.17 as of Dec. 2025, which is 53% below its 10-year median of 2,179.73. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Starpharma Holdings ranks better than 82.89% on this metric.
The historical rank and industry rank for Starpharma Holdings's Days Payable or its related term are showing as below:
ASX:SPL'
s Days Payable Range Over the Past 10 Years
Min: 694.53 Med: 2179.73 Max: 5177.62
Current: 694.53
During the past 13 years, Starpharma Holdings's highest Days Payable was 5177.62. The lowest was 694.53. And the median was 2179.73.
ASX:SPL's Days Payable is ranked better than 82.89% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs ASX:SPL: 694.53
Starpharma Holdings's Days Payable
declined
from Dec. 2024 (1,410.70) to Dec. 2025 (1,034.17).
It may suggest that Starpharma Holdingsaccelerated paying its suppliers.
Starpharma Holdings Days Payable Related Terms
Starpharma Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SPL vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Starpharma Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Starpharma Holdings's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings (ASX:SPL) has a Days Payable of 1,034.17 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Starpharma Holdings and its competitors. This is 53% below median its historical median of 2,179.73. Over the past decade, Starpharma Holdings' Days Payable has ranged from 694.53 to 5,177.62. According to the industry distribution chart, Starpharma Holdings ranks #121 out of 707 companies in the Biotechnology industry, placing it in the top 17.1%.
Is Starpharma Holdings' Days Payable too high?
Starpharma Holdings' current Days Payable of 1,034.17 is 53% below median its 10-year median of 2,179.73. Over the past 10 years, this metric has ranged from a low of 694.53 to a high of 5,177.62. The Biotechnology industry median Days Payable is 113.76. Starpharma Holdings' value of 1,034.17 is 809.1% above this industry median. Based on the distribution chart, Starpharma Holdings ranks #121 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #121 out of 707 companies for Days Payable. This places Starpharma Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Starpharma Holdings' value of 1,034.17 is 809.1% above this benchmark. Historically, Starpharma Holdings' own Days Payable has ranged from 694.53 to 5,177.62 over the past decade. While the company's 10-year median is 2,179.73 vs. the industry median of 113.76, Starpharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starpharma Holdings's current Days Payable of 1,034.17 is 809.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current Days Payable is 1,034.17, which is 53% below median its own 10-year median of 2,179.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Days Payable is 1,034.17, which is 53% below median its 10-year median of 2,179.73 and 809.1% above the Biotechnology industry median of 113.76. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Days Payable is 1,034.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
Days Payable: 1,034.17 (53% below median its 10-year median of 2,179.73)
GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
Industry Position: 809.1% above the Biotechnology median (#121 of 707)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
52GF Score
Get the complete analysis for ASX:SPL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
